Israel’s Therapix Biosciences (reported here previously) is working with the University of Calgary to evaluate the pain relief effect of its THX-160 analgesic. In pre-clinical studies, THX-160 was in some instances even more effective than high-dose morphine. http://therapix.investorroom.com/2020-12-02-Therapix-Biosciences-to-Collaborate-with-The-University-of-Calgary-to-Further-Examine-its-Proprietary-Drug-Candidate-THX-160-for-Pain https://therapixbio.com/

Israel’s Therapix Biosciences is conducting a proof-of-concept Phase II clinical study with the Hannover Medical School, of its lead compound THX-TS01 for 20 patients suffering from Tourette Syndrome. http://www.prnewswire.com/news-releases/therapix-biosciences-and-the-hannover-medical-school-enter-into-an-investigator-initiated-clinical-trial-agreement-to-assess-the-effect-of-txh-ts01-in-patients-with-tourette-syndrome-300453033.html

Israel’s Therapix Biosciences has developed a unique tablet for sublingual (under the tongue) administration of THC. A clinical trial of this tablet is anticipated to commence early 2017 for treatment of impairments in cognitive functioning, including early stages of Alzheimer’s … Continue reading →